Medtronic’s recall of its Sprint Fidelis defibrillator lead potentially affects 235,000 people. According to reports, approximately 2,000 of them are under the age of 21 and may be at greater risk than adults implanted with the same product.

Why younger patients are at greater risk

According to a report in the Wall Street Journal, the leads that attach a defibrillator device (used to shock the heart into a normal rhythm) tend to “come under greater stress in more active people, including kids, adolescents and younger adults.”

The recall has placed a great emphasis on the fact that some of the Fidelis leads can fracture and cause the defibrillator to shock the heart unnecessarily (some patients have reported being shocked dozens of times without cause) or to fail in shocking the heart when needed.

According to data released by the company, the Sprint Fidelis failure rate was higher, 3.8%, in patients under the age of 21 than for the entire population, which had a failure rate of 2.3%. Younger adults and children are also at a greater risk because their heart beats faster and may place more stress on the leads that are attached to their hearts.

What Medtronic is doing

Medtronic has said that it will pay to replace any defective leads. Patients should see their doctors immediately to see if they have a lead that might be defective. The defective leads have the following identification numbers: 6930, 6931, 6948 and 6949.

We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.

Continuing the battle with Big Pharma

The entire Beasley Allen staff had our personal interest at heart. We were part of the family of a down to earth, trustworthy, understanding law firm. Thank you, Beasley Allen, for continuing the battle with Big Pharma.